Gestational Trophoblastic Neoplasia: A FIGO Score of Exactly Six
The FIGO risk-scoring system for gestational trophoblastic neoplasia was built and validated as a composite — the whole score predicts treatment response, not any one input alone. Hers lands at exactly 6, low-risk by one point, carried there by a pretreatment hCG high enough that it's hard not to look at that single number and want more than the score itself calls for.
Priyanka D., 27, works as a dental hygienist, a job she went back to eleven weeks after a molar pregnancy was evacuated, mostly because sitting at home with nothing to do but check a phone app for her next hCG level result felt worse than a full patient schedule. That hCG never fell to zero the way it was supposed to after evacuation — it plateaued, then began rising again, meeting the criteria for post-molar gestational trophoblastic neoplasia and triggering the FIGO risk-scoring workup that now determines how aggressively she is treated.
The FIGO scoring system assigns points across several variables — age, type of antecedent pregnancy, interval since that pregnancy, pretreatment hCG level, size of the largest tumor, site and number of metastases — and sums them into a single number: 6 or below is low-risk, treated with single-agent chemotherapy; 7 or above is high-risk, treated with combination EMA-CO from the start. Priyanka's total comes to exactly 6, low-risk by a single point, but that total is carried there disproportionately by one input: her pretreatment hCG sits at the very top of its scoring band, just under the threshold that would have carried her into the high-risk category outright. The scoring system was built and validated as a composite specifically because individual risk factors don't reliably predict treatment resistance on their own — GOG-174, the trial comparing single-agent options within the low-risk category, found biweekly pulsed actinomycin-D achieved a meaningfully higher primary complete response rate than weekly methotrexate, at the cost of more toxicity, a genuinely separate question from whether single-agent therapy of either kind is the right category for her at all. What her actual chart doesn't answer is whether a hCG value sitting at the edge of its own scoring band, in an otherwise low-risk composite, is a reason to reach past that composite's own validated recommendation. Her hCG falls in the band spanning 10,000 to 100,000 mIU/mL, worth two of her six total points on its own; the scoring system assigns no value of 3 to any variable, so a single-decade rise past 100,000 would jump that item straight from 2 points to 4 and carry her total to 8 — high-risk not by a hair but by two clear points, on the strength of that one component alone.
One number carrying more weight than the total
I'd treat her as low-risk, per the score: single-agent actinomycin-D, given GOG-174's higher primary response rate over weekly methotrexate. The FIGO score's entire predictive power comes from being used as a composite. If we start overriding a validated total because one input looks high in isolation, we're not really using the score at all — we're using clinical impression and calling it a score.
I'd start combination EMA-CO. Her hCG sits at the very top of its scoring band, and the band above it is worth four points, not three — a single-decade rise would put her at 8, not 7, well clear of the high-risk line rather than a hair over it. A score of 6 reached that way reflects a different tumor burden than a 6 built from several moderate inputs, even if the composite number reads the same. I don't want to find out at week six that single-agent therapy wasn't enough.
"The score is validated as a composite" is true, but validation studies report aggregate performance across many patients — they don't guarantee every individual patient with the same total score carries the same actual risk, especially when the components that produced it look this different.
I don't think you need to choose between trusting the score and taking her hCG seriously. Start actinomycin-D per the validated low-risk regimen, but set an explicitly lower threshold for calling this resistant — any hCG plateau or rise at the first reassessment, rather than waiting through the standard low-risk resistance timeline. That respects the score's own composite design while treating the thing that's actually worrying you as a monitoring variable instead of a regimen-selection override.
Agreed: biweekly pulsed actinomycin-D started per her validated FIGO low-risk score, with weekly hCG monitoring and an explicitly lowered threshold for declaring treatment resistance and escalating to combination therapy.
Fully agreed on the plan, though not on the underlying reasoning: the medical oncologist's discomfort with treating her as straightforwardly low-risk was addressed through tighter monitoring rather than resolved on the merits — both voices accepted the compromise as sufficient without either fully conceding the other's read of what her hCG value actually meant.